Opus Genetics is trading 5% down at $3.31 today amid broader weakness in the biotech sector and risk assets.
- There are no fresh company-specific announcements, FDA decisions, or earnings reports today to account for the price move.
- The decline appears driven by general sector volatility and cautious investor sentiment toward small-cap clinical-stage biotech names.